BIOMAT Database Logo BIOMAT Database Logo

Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. 1990

H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Department of Internal Medicine, Hiroshima University, Japan.

Regulatory effects of glucocorticoids (dexamethasone) on myeloma cells as well as bone resorption in multiple myeloma were investigated. Glucocorticoids significantly inhibited proliferation of myeloma cells, and decreased the messenger RNA (mRNA) expressions of interleukin-6 (IL-6) and secretory type immunoglobulin G (IgG). The inhibitory effects of glucocorticoids on myeloma cell proliferation could be due to the decreased expression of IL-6 mRNA, decreased IL-6 production, and thus suppression of autocrine growth by IL-6, which is an autocrine growth factor for myeloma cells as reported previously (Nature 332:83, 1988). Glucocorticoids also inhibited M-protein secretion by decreasing the levels of secretory type Ig mRNA. On the other hand, because IL-1 beta rather than lymphotoxin is considered to be a major osteoclast activating factor (OAF) produced by myeloma cells, and glucocorticoids decreased the expression of IL-1 beta mRNA and markedly suppressed the bone resorbing activity induced by IL-1 beta OAF in 45Ca-release bone resorption assay, it is suggestive that glucocorticoids could inhibit bone resorption induced by IL-1 beta OAF in multiple myeloma. Therefore, from these data it is concluded that glucocorticoids could be more effective chemotherapeutic agents in multiple myeloma than we expected, especially with regards to the inhibitory effects on proliferation and M-protein secretion from myeloma cells, as well as bone resorption by myeloma cells.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D010010 Osteoclasts A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption. Odontoclasts,Cementoclast,Cementoclasts,Odontoclast,Osteoclast
D010014 Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium. Osteolyses
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
July 1996, Experimental hematology,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.
May 1981, The Journal of clinical investigation,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Effects of glucocorticoids on osteoclast-activating factor.
November 1978, The Journal of laboratory and clinical medicine,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
[Activity of bone resorption for interleukin-1, epithelium thymocyte-activating factor and fibroblast thymocyte-activating factor].
November 1990, Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Osteoclast activating factor is now interleukin-1 beta: historical perspective and biological implications.
April 1988, Journal of oral pathology,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
[Osteoclast activating factor - a new humoral agent influencing pathological bone resorption].
August 1982, Casopis lekaru ceskych,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta.
October 1985, Journal of immunology (Baltimore, Md. : 1950),
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae.
June 1988, Arthritis and rheumatism,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Effect of osteoclast activating factor from human leukocytes on bone metabolism.
August 1975, The Journal of clinical investigation,
H Ishikawa, and H Tanaka, and K Iwato, and O Tanabe, and H Asaoku, and M Nobuyoshi, and I Yamamoto, and M Kawano, and A Kuramoto
Mouse interleukin-1 receptor antagonist induced by Actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation.
February 1994, Infection and immunity,
Copied contents to your clipboard!